Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDC-DXd
- Development stage
- Unknown
- Lead developer
- Var2 Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDC-DXd is a non-targeting control drug conjugate (CDC) used in preclinical oncology research to evaluate the specificity and efficacy of antibody-drug conjugates (ADCs) targeting oncofetal chondroitin sulfate (ofCS). It consists of an irrelevant albumin-binding domain (ABD) protein scaffold (ABDwt-SpyC-2Cys) conjugated to the cytotoxic payload Deruxtecan (DXd) via a cathepsin-cleavable glycine-glycine-phenylalanine-glycine (ggfg) linker. CDC-DXd serves as a negative control to distinguish between the targeted anti-tumor activity of Vartumab-DXd and non-specific effects such as systemic payload release or bystander killing. In experimental models of melanoma and lung cancer, CDC-DXd typically demonstrates minimal anti-tumor activity compared to the targeted Vartumab-DXd, thereby validating the therapeutic window and targeting mechanism of the ofCS-directed ADC.
- Other names
- Control Drug Conjugate-Deruxtecan
02
Targets
ofCS (Oncofetal chondroitin sulfate)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on CDC-DXd.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDC-DXd.